As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Tocilizumab (TCZ) for Severe COVID-19
The purpose of this study is to evaluate TCZ in combination with standard of care in hospitalized patients with severe COVID-19 pneumonia. Randomized participants will receive one infusion of TCZ 8mg/kg.
In order to participate you must meet the following criteria:
- Have signed informed consent form (if capable of giving consent), or, when the patient is not capable of giving consent, by his or her legal/authorized representative.
- Are at least 18 years of age at time of signing the informed consent form.
- Are hospitalized with COVID-19 pneumonia confirmed per a positive PCR of any specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan.
- Have SpO2 <=93% or PaO2/FiO2 <300 mmHg.
This is a partial list of elgibility requirements.